Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.33 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948013 | 0.85 | MAPK14 (0.39) | GPR139ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL2947996 | 0.85 | MAPK14 (0.39) | GPR139ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL2948367 | 0.85 | MAPK14 (0.39) | GPR139ADRB2ADRB1ADRB3CES2 | |
| SCHEMBL3019789 | 0.85 | CES2 (0.34) | GPR139CES2CES1 | |
| SCHEMBL2944402 | 0.84 | PNMT (0.38) | GPR139ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL2946661 | 0.83 | CES2 (0.33) | SMN1; SMN2GPR139CES2CES1 | |
| SCHEMBL2946482 | 0.81 | CES2 (0.40) | NPC1GPR139ADRB2ADRB1ADRB3 | |
| SCHEMBL2943148 | 0.80 | CES2 (0.43) | NPC1GPR139LMNACES2CES1 | |
| SCHEMBL2947177 | 0.80 | CES2 (0.43) | NPC1GPR139LMNACES2CES1 | |
| SCHEMBL2941752 | 0.79 | CES2 (0.40) | GPR139ADRB2ADRB1ADRB3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076367-B2 | Benzimidazolylidene propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709519-B2 | Benzimidazolylidene propane-1,3 dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1752452-A9 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1752452-A1 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GPER1, GNRHR, AR | NPC1 2645/4885RAB9A 4299/4885SMN1; SMN2 1757/4885 |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | GPER1, GNRHR, AR | NPC1 2881/4885RAB9A 4448/4885SMN1; SMN2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.